This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DAMRON, T. A.
Right arrow Articles by SIM, F. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by DAMRON, T. A.
Right arrow Articles by SIM, F. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?
The Journal of Bone and Joint Surgery (American) 82:114-26 (2000)
© 2000 The Journal of Bone and Joint Surgery, Inc.

Instructional Course Lecture

Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Operative Treatment for Metastatic Disease of the Pelvis and the Proximal End of the Femur*{dagger}

TIMOTHY A. DAMRON, M.D.{ddagger}, SYRACUSE, NEW YORK and FRANKLIN H. SIM, M.D.§, ROCHESTER, MINNESOTA

An Instructional Course Lecture, American Academy of Orthopaedic Surgeons

The first 150 words of the full text of this article appear below.


   Introduction
 
The prognosis for patients who have invasive cancer continues to improve. According to the statistics of the American Cancer Society3 for 1988 through 1992, the five-year survival rate for patients who have prostate cancer is 90 percent for whites and 75 percent for blacks and the five-year survival rate for patients who have breast cancer is 86 percent for whites and 70 percent for blacks. However, estimates suggest that 50 percent of the 1,228,600 new cases of invasive cancer diagnosed each year will eventually metastasize to bone3.

Many of these metastatic lesions involve the pelvis and the proximal end of the femur. In fact, the pelvis is second only to the spine in terms of the frequency of osseous involvement by metastatic disease, and the proximal end of the femur is the most common site of long-bone involvement by metastatic disease. While the recent introduction of bisphosphonates, which counteract . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 JBJSHome page
M. M. Schneiderbauer, M. von Knoch, C. D. Schleck, W. S. Harmsen, F. H. Sim, and S. P. Scully
Patient Survival After Hip Arthroplasty for Metastatic Disease of the Hip
J. Bone Joint Surg. Am., August 1, 2004; 86(8): 1684 - 1689.
[Abstract] [Full Text] [PDF]